{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Metabolic Enzyme & Protease > TipifarnibCAS：192185-72-1
Molecular Formula：C27H22Cl2N4O
Molecular Weight：489.4
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥99%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 192185-72-1 |
| Name | Tipifarnib |
| Molecular Formula | C27H22Cl2N4O |
| Molecular Weight | 489.4 |
| Solubility | Soluble in DMSO |
| Purity | ≥99% |
| Appearance | White to yellow Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD07772347 |
| SMILES | O=C1N(C2=C(C(C3=CC=CC(Cl)=C3)=C1)C=C(C=C2)[C@@](N)(C4=CN=CN4C)C5=CC=C(C=C5)Cl)C |
| Target Point | Farnesyl Transferase |
| Passage | Metabolic Enzyme&Protease |
| Background | Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor. |
| Biological Activity | Tipifarnib 是一种有效的, 特异性的 farnesyltransferase (FTase) 抑制剂, IC50 值为 0.6 nM[1-6]。 |
| IC50 | IC50: 0.6nM (FTase) [1-6] |
| Data Literature Source | [1]. Hechinger AK， et al. Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells. Haematologica. 2012 Jul 16. [2]. Bai F， et al. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012 Apr; 61 (4) :523-33. [3]. Kotsianidis I， et al. In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors. Acta Haematol. 2008; 120 (1) :51-6. [4]. Martin LA， et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007 Sep; 6 (9) :2 [5]. Krzykowska-Petitjean K， et al. Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells. J Cancer Res Clin Oncol. 2012 Mar; 138 (3) :537-44. [6]. End DW， et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1; 61 (1) :131-7. |
| Unit | Bottle |
| Specification | 5mg 10mg 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
